 1. Patients with histologic confirmation of invasive HER2neu-negative breast cancer IHC 0-1 or FISH-negative that have received complete anthracycline and taxane neoadjuvant systemic therapy and that at the time of surgery are expected to have significant residual disease. Therapy should include at least 4 cycles of an anthracycline-based regimen AC, FAC, FEC and 12 weeks of a taxane-based regimen weekly paclitaxel, every 3-week docetaxel. 